Literature DB >> 31388277

Plasmablastic Lymphoma Versus EBV-Positive Myeloma.

Divya Bansal1, Neha Singh1, Narendra Agrawal2, Anurag Mehta1.   

Abstract

Entities:  

Year:  2019        PMID： 31388277      PMCID： PMC6646433          DOI： 10.1007/s12288-019-01116-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  4 in total

1.  Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.

Authors:  Janice S Ahn; Ryan Okal; Jeffrey A Vos; Matthew Smolkin; Abraham S Kanate; Flavia G Rosado
Journal:  J Clin Pathol       Date:  2017-03-01       Impact factor: 3.411

Review 2.  The biology and treatment of plasmablastic lymphoma.

Authors:  Jorge J Castillo; Michele Bibas; Roberto N Miranda
Journal:  Blood       Date:  2015-01-30       Impact factor: 22.113

Review 3.  Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.

Authors:  Charles M Harmon; Lauren B Smith
Journal:  Arch Pathol Lab Med       Date:  2016-10       Impact factor: 5.534

4.  Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV.

Authors:  Sheng-Tsung Chang; Yung-Liang Liao; Chin-Li Lu; Shih-Sung Chuang; Chin-Yang Li
Journal:  Am J Clin Pathol       Date:  2007-08       Impact factor: 2.493
  4 in total
  2 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

Review 2.  Epstein barr virus encodes miRNAs to assist host immune escape.

Authors:  Weiming Li; Cong He; Jiayi Wu; Dazhi Yang; Weihong Yi
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.